WO1992001706A1 - Nouveaux derives de la 6-methyl 19-nor progesterone, substitue en 3 et leur procede d'obtention - Google Patents
Nouveaux derives de la 6-methyl 19-nor progesterone, substitue en 3 et leur procede d'obtention Download PDFInfo
- Publication number
- WO1992001706A1 WO1992001706A1 PCT/FR1991/000587 FR9100587W WO9201706A1 WO 1992001706 A1 WO1992001706 A1 WO 1992001706A1 FR 9100587 W FR9100587 W FR 9100587W WO 9201706 A1 WO9201706 A1 WO 9201706A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- pregna
- diene
- general formula
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
Definitions
- the present invention relates to the field of organic chemistry and more particularly to that of therapeutic chemistry.
- R 1 is hydrogen and R 2 is an OR 3 radical in which R 3 is hydrogen or the acyl residue of an organic carboxylic acid having from 1 to 12 carbon atoms
- R 1 and R 2 are each a lower alkoxy radical
- R 1 is hydrogen and R 2 is an OR 3 radical in which R 3 has the definitions provided above
- R 5 is an alkylene chain having from 2 to 4 carbon atoms which may be substituted by one or two groups chosen from the group consisting of an alkoxy carbonyl, an aminocarbonyl, a cyano, a carboxy or a lower alkyl, aliphatic or cyclic and Ac has the previous meanings.
- R is a residue of an aliphatic, (cycloalkyl) alkyl, aromatic or arylaliphatic acid.
- the hydrocarbon chain can be linear or branched. It has from 1 to 12 carbon atoms. It may include unsaturation.
- the radical Ac is a residue of organic aliphatic acid in a straight or branched chain, having from 2 to 6 carbon atoms, such as an acetyl, butyryl, isobutyryl, hexanoyl, caproyl, pivaloyl or valeroyl radical.
- a C is a residue of arylaliphatic organic acid, the aliphatic chain has from 1 to 10 carbon atoms in a straight or branched chain.
- R 4 is an alkyl radical, it has from 1 to 4 carbon atoms in a straight or branched chain such as methyl, ethyl, isopropyl or terbutyl.
- R 4 is a carboxyalkyl
- the alkyl chain has from 1 to 4 carbon atoms such as methyl, ethyl, isopropyl or butyl.
- the configuration of the substituents R 1 and R 2 is arbitrary. It can be ⁇ H ⁇ -R 2 or ⁇ H ⁇ R 2 . It depends mainly on the nature of the reducing agent which provides a hydroxylated compound.
- R 4 is a carboxyalkyl group
- the carboxylic group can be salified with an inorganic or organic base to provide salts which are soluble in water or, on the contrary, salts which are sparingly soluble in water. Mention may be made, as water-soluble salts, of the alkali metal salts, the ammonium salts, the triethanolamine salts, the N-methylglucamine salts, the glucosamine salts, the sarcosine salts and the tromethamine salts.
- R 4 O - NH 2 (III) in which R 4 is hydrogen, a lower alkyl or lower carboxyalkyl radical
- the invention also relates to a process for the preparation of compounds of general formula I in which R 1 and R 2 together form an optionally substituted alkylene dioxy chain or each represent a lower alkoxy radical, which consists in subjecting a
- 3,20-dioxo 6-methyl 17 ⁇ -acyloxy pregna 4,6-diene of general formula II to the action of a glycol, vicinal or not, or of a lower alkanol in the presence of an organic acid and / or of a dehydrating agent such as an alkyl orthoformate and then neutralizes the reaction mixture at the end of the reaction with a tertiary amine.
- the invention can also be defined by the following characteristics:
- the reducing agent which selectively reduces the compound of formula II to 3 is your mixed metal hydride alkali metal borohydride, an alkali metal aluminohydride, or an alkali metal in a low molecular weight alkanol.
- the functional derivative of carboxylic acid is an acid anhydride, an acid chloride or a mixed anhydride of aliphatic, aromatic or aryl aliphatic carboxylic acid having from 1 to 10 carbon atoms in the alkyl chain and operates in the presence of an organic base such as pyridine, a picoline, 4-dimethylamino pyridine, triethylamine, N-methylmorpholine or N-methylpyrolidone.
- the ketalization reaction is carried out at a temperature varying from 20 ° to 100 ° for a period ranging from 5 min to 24 hours, in the presence of an acid catalyst.
- the invention also extends to pharmaceutical compositions containing, as active principle, at least one compound of general formula I in admixture or in combination with an inert non-toxic, pharmaceutically acceptable excipient or vehicle.
- the compounds according to the invention have advantageous pharmacological properties, in particular as progesterone agents.
- contraceptive drugs can also enter into the composition of contraceptive drugs either alone, or combined with an estrogen such as mestranol or quingestanol.
- compositions according to the invention are those which are suitable for parenteral, oral, rectal, permucosal or percutaneous administration.
- the compounds of general formula I can also serve as a mode of isolation or purification for the corresponding 3-ketone compounds.
- This product is used without further purification for esterifications.
- the color of the solution turns from yellow to green (cooling color) then to dark red.
- the progress of the reaction is checked by TLC every hour (eluent: CH 2 Cl 2 / AcOEt 95/5 and 0.5% EUN); the disappearance of the 3-ketone derivative (Rf 0.3) is effective after 4 h of reaction; the formation of two tasks was observed (Rf 0.8 and 0.5).
- the mixture is taken up in 200 ml of diethyl ether and then washed 5 times (70 ml) with a solution of NaHCO 3 at 2/1000.
- the organic phase is dried over anhydrous sodium sulfate and then evaporated in vacuo.
- the oily product taken up in 100 ml of anhydrous ethanol (containing 1 ml of triethylamine), the ketal precipitates after 10 minutes.
- the solid is filtered on fried glass and dried under vacuum.
- reaction mixture is brought to 65 ° C for 5 min (whitish solution) and 17 mg (89 ⁇ mol) p.toluene sulfonic acid are added in one portion (purple solution). Agitation is maintained for 10 min at this temperature then a drop of triethylamine is added to basify the reaction medium in order to prevent any hydrolysis of the ketal obtained.
- the reaction medium is hydrolyzed with 10 ml of a saturated sodium bicarbonate solution and extracted with ethyl acetate.
- the residual oily product is taken up in 5 ml of anhydrous methanol and the product precipitates.
- the reaction medium is filtered and the filtrate is dried under vacuum with a vane pump. 1.96 g of 3.3-ketal are recovered.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR90/09278 | 1990-07-20 | ||
FR9009278A FR2664895B1 (fr) | 1990-07-20 | 1990-07-20 | Nouveaux derives de la 6-methyl 19-nor progesterone, substitues en 3 et leur procede d'obtention. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992001706A1 true WO1992001706A1 (fr) | 1992-02-06 |
Family
ID=9398932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1991/000587 WO1992001706A1 (fr) | 1990-07-20 | 1991-07-17 | Nouveaux derives de la 6-methyl 19-nor progesterone, substitue en 3 et leur procede d'obtention |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0491924A1 (fr) |
FR (1) | FR2664895B1 (fr) |
IE (1) | IE912539A1 (fr) |
IL (1) | IL98901A0 (fr) |
MA (1) | MA22229A1 (fr) |
MX (1) | MX9100291A (fr) |
OA (1) | OA09566A (fr) |
PT (1) | PT98415A (fr) |
TN (1) | TNSN91060A1 (fr) |
WO (1) | WO1992001706A1 (fr) |
YU (1) | YU126591A (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2695826A1 (fr) * | 1992-09-21 | 1994-03-25 | Theramex | Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention. |
NO327366B1 (no) * | 2002-02-07 | 2009-06-15 | Novartis Ag | Amider og fremgangsmåter for fremstilling derav |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2219783A1 (fr) * | 1973-03-01 | 1974-09-27 | Ortho Pharma Corp | |
FR2271833A1 (fr) * | 1974-05-21 | 1975-12-19 | Gastaud Jean Marie | |
EP0085900A2 (fr) * | 1982-02-05 | 1983-08-17 | Schering Aktiengesellschaft | Procédé de préparation de 6-methyl-delta-4,6-3-ceto stéroides |
WO1985001504A1 (fr) * | 1983-10-04 | 1985-04-11 | Theramex S.A. | NOUVEAU PROCEDE DE PREPARATION DE DERIVES DE LA SERIE DE LA 17alpha-HYDROXY 19-NOR-PROGESTERONE |
-
1990
- 1990-07-20 FR FR9009278A patent/FR2664895B1/fr not_active Expired - Fee Related
-
1991
- 1991-07-17 EP EP91913372A patent/EP0491924A1/fr not_active Withdrawn
- 1991-07-17 WO PCT/FR1991/000587 patent/WO1992001706A1/fr not_active Application Discontinuation
- 1991-07-18 MA MA22504A patent/MA22229A1/fr unknown
- 1991-07-18 YU YU126591A patent/YU126591A/sh unknown
- 1991-07-19 TN TNTNSN91060A patent/TNSN91060A1/fr unknown
- 1991-07-19 IE IE253991A patent/IE912539A1/en unknown
- 1991-07-19 MX MX9100291A patent/MX9100291A/es unknown
- 1991-07-21 IL IL98901A patent/IL98901A0/xx unknown
- 1991-07-22 PT PT98415A patent/PT98415A/pt not_active Application Discontinuation
-
1992
- 1992-03-17 OA OA60166A patent/OA09566A/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2219783A1 (fr) * | 1973-03-01 | 1974-09-27 | Ortho Pharma Corp | |
FR2271833A1 (fr) * | 1974-05-21 | 1975-12-19 | Gastaud Jean Marie | |
EP0085900A2 (fr) * | 1982-02-05 | 1983-08-17 | Schering Aktiengesellschaft | Procédé de préparation de 6-methyl-delta-4,6-3-ceto stéroides |
WO1985001504A1 (fr) * | 1983-10-04 | 1985-04-11 | Theramex S.A. | NOUVEAU PROCEDE DE PREPARATION DE DERIVES DE LA SERIE DE LA 17alpha-HYDROXY 19-NOR-PROGESTERONE |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2695826A1 (fr) * | 1992-09-21 | 1994-03-25 | Theramex | Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention. |
WO1994006437A1 (fr) * | 1992-09-21 | 1994-03-31 | Laboratoire Theramex S.A. | Implants sous-cutanes a base de derives de nomegestrol |
AP497A (en) * | 1992-09-21 | 1996-05-28 | Laboratoire Theramex | Novel subcutaneous implants based on nomegestrol derivatives and the processes for their production. |
CN1095667C (zh) * | 1992-09-21 | 2002-12-11 | 泰拉姆斯实验室 | 基于去甲基甲地孕酮衍生物的新颖组合物及其生产方法 |
NO327366B1 (no) * | 2002-02-07 | 2009-06-15 | Novartis Ag | Amider og fremgangsmåter for fremstilling derav |
Also Published As
Publication number | Publication date |
---|---|
FR2664895B1 (fr) | 1992-10-30 |
MA22229A1 (fr) | 1992-04-01 |
YU126591A (sh) | 1994-05-10 |
OA09566A (fr) | 1993-01-31 |
PT98415A (pt) | 1992-05-29 |
IL98901A0 (en) | 1992-07-15 |
TNSN91060A1 (fr) | 1992-10-25 |
EP0491924A1 (fr) | 1992-07-01 |
MX9100291A (es) | 1992-02-28 |
FR2664895A1 (fr) | 1992-01-24 |
IE912539A1 (en) | 1992-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR1449628A (fr) | Procédé de préparation d'indoles polynucléaires désacylés, notamment d'esters de la série de la désacétyl-vincaleucoblastine et de la désacétyl-vincristine | |
LU88001A1 (fr) | Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires | |
CA1193247A (fr) | Procede de preparation de nouveaux derives du 3-amino- pregn-5ene et de leurs sels | |
WO1999035155A1 (fr) | Nouveaux amides aromatiques, leur procede de preparation et leur application comme medicaments | |
AU607100B2 (en) | New androstane 17-carboxylic acid ester, process for their preparation and drugs containing them | |
CA2539849A1 (fr) | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique | |
KR100640066B1 (ko) | 모메타손 푸로에이트의 제조방법 | |
EP0272478B1 (fr) | Dérivés d'acide glycyrrhétinique et leur utilisation | |
CA2576393A1 (fr) | Nouveaux derives du 3,5-seco-4-nor-cholestane et leurs utilisations | |
WO1992001706A1 (fr) | Nouveaux derives de la 6-methyl 19-nor progesterone, substitue en 3 et leur procede d'obtention | |
EP1297835B1 (fr) | Dérivés de benzo[b]pyrano[3,2-h]acridin-7-one, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP0772630B1 (fr) | Derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP0104631B1 (fr) | Dérivés de clavulone, leur procédé de préparation et leur application | |
TWI334781B (en) | Stereospecific synthesis of sapogenins | |
CH629821A5 (fr) | Derives semi-synthetiques de l'oleandomycine et leur procede de preparation. | |
EP0045251A1 (fr) | Nouveaux dérivés de la thiazolo (3,2-a) pyrimidine, leur préparation et les médicaments qui les contiennent | |
EP1561753A2 (fr) | Dérivés de benzo[b]chroménonapthyridin-7-one et de pyrano[2',3':7,8]quino[2,3-b]quinoxalin-7-one, leur procédé de préparation, les compositions pharmaceutiques qui les contiennent et leurs propriétés antitumorales pour le traitement du cancer | |
FR2638458A1 (fr) | Nouveaux derives de la tylosine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
JPH02129199A (ja) | エライオフイリンのエノールエーテル類およびその製法 | |
CH629823A5 (fr) | Derives steroides substitues en 11beta et leur procede de preparation. | |
FR2646081A1 (fr) | ||
JP2834721B2 (ja) | 17α−シアノメチルエストラ−4,9−ジエン誘導体、その製造方法および該化合物を含有する医薬品 | |
FR2581996A1 (fr) | Nouveaux derives 6-substitues de 6h-dibenzo(b, d)thiopyranne utiles notamment immunomodulateurs et antiviraux et leur preparation | |
FR2645864A1 (fr) | Nouveaux derives alcoyles en 17/21 de la 19-nor progesterone, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant | |
CH633714A5 (fr) | Derives 17alpha-acetyleniques de l'androst 4-ene, procede de prepararation et compositions pharmaceutiques. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BG BR CA CS FI HU JP KR NO PL RO SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991913372 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991913372 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991913372 Country of ref document: EP |